Neuromedin U: A New Way Neuroendocrine Prostate Cancer May Hide From the Immune System

/in /by

Neuroendocrine prostate cancer is one of the most aggressive forms of the disease and remains particularly difficult to treat. A new Oncogene study has identified a possible mechanism that helps these tumours suppress the immune response, centred on a molecule called Neuromedin U, or NMU. In mouse models of neuroendocrine prostate cancer, the researchers found […]

Read more

A “Plug-and-Play” CAR-T That Could Be Updated as Cancer Changes

/in , /by

CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable. The researchers created […]

Read more

B7-H3 May Be Doing More Than Marking Prostate Cancer

/in /by

B7-H3 has become one of the most interesting targets in advanced prostate cancer, especially for antibody-drug conjugates and other targeted treatments. A new Cancer Discovery study suggests that B7-H3 may not simply sit on the surface of tumour cells: it may actively help the cancer suppress the immune system and resist treatment. The researchers found […]

Read more

New Phase 2 trial for JNJ-101556143 aka HLD-0915 in mCRPC / mAPMR Prostate Cancer

/in , , /by

A new phase 2 trial will test JNJ-101556143, also known as HLD-0915, in men with metastatic prostate cancer that has become resistant to androgen-pathway treatment. The study plans to enrol about 100 patients and will evaluate whether the drug can produce objective tumour responses, making this a clear step beyond the earlier dose-finding programme. JNJ-101556143 […]

Read more

JUR-003 Enters Phase 1 Trial in Metastatic Prostate Cancer

/in , , , , /by

A new first-in-human phase 1 trial, has been posted for JUR-003 in metastatic prostate cancer. The study plans to enrol up to 210 patients and includes dose-escalation and dose-expansion cohorts in mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease. JUR-003 will be given intravenously, with the initial goals of defining safety, pharmacokinetics and a […]

Read more

ENV105 Phase 2 Trial for mCRPC: Can Prostate Cancer Be Made Sensitive to Hormone Therapy Again?

/in , , /by

We already discussed ENV105 (carotuximab) in a previous ProstateWarriors article, when the safety lead-in of its phase 2 trial in metastatic castration-resistant prostate cancer was completed. Since then, the programme has produced its first meaningful efficacy signal, making it worth revisiting. ENV105 targets CD105, a protein that appears to become more active as prostate cancer […]

Read more

BUB1B and CENP-E: A New Vulnerability in Enzalutamide-Resistant Prostate Cancer

/in /by

A new preclinical study published in Cancer Research has identified a possible way to attack prostate cancer that has become resistant to castration and enzalutamide. The work focuses on BUB1B, a protein involved in controlling cell division, and CENP-E, one of the proteins it helps regulate. When researchers lowered BUB1B levels, resistant prostate cancer cells […]

Read more

Terbinafine: An Old Antifungal Enters a Phase 2 Prostate Cancer Trial

/in , , , , /by

An inexpensive antifungal drug that has been used for decades is now being tested as a prostate cancer treatment. The phase 2 TerbinaPro trial is evaluating terbinafine in men whose prostate cancer has returned biochemically after previous treatment. Behind this unusual drug-repurposing trial lies an intriguing discovery about how prostate cancer produces cholesterol. The target […]

Read more